Loading...
•
Dec 31, 2023
Bicycle Q4 2023 Earnings Report
Bicycle Therapeutics reported financial results for Q4 2023 and provided corporate updates.
Key Takeaways
Bicycle Therapeutics reported its Q4 and full year 2023 financial results, highlighting progress across its oncology portfolios and discovery pipeline. The company's cash and cash equivalents were $526.4 million as of December 31, 2023, expected to provide financial runway into 2026.
Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer is now active and recruiting patients.
Initial clinical data for BT8009 showed a promising response and differentiated safety profile.
R&D Day outlined near-term strategic priorities and highlighted the breadth of Bicycle® platform technology.
Stephen Sands was appointed to the Board of Directors.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...